[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:embryonal-neoplasm":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":29,"states":30},"Embryonal Neoplasm",3,[7,15,22],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT05278208","Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors",[11],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:18:21.216897Z","2026-07-24T01:27:14.928126Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT07017816","A Phase 0\u002F1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.",[19],"Early Phase 1","2026-08-26T02:17:32.059863Z","2026-05-05T02:43:27.319544Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":27,"content_modified":28},"NCT06915727","An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors",[26],"Phase 3","2026-08-26T02:17:00.709807Z","2026-05-05T02:43:27.987617Z",[],[]]